---
title: "Explainable Deep Learning Identifies Distributed Neurodegeneration Signatures of Neuropsychiatric"
id: "medrxiv-13-explainable-deep-learning-reveals-distributed-neurodegeneration-signatures-of"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-13-explainable-deep-learning-reveals-distributed-neurodegeneration-signatures-of"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.24.26361256v1?rss=1"
published_at: "2026-08-27T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Explainable Deep Learning Identifies Distributed Neurodegeneration Signatures of Neuropsychiatric
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-13-explainable-deep-learning-reveals-distributed-neurodegeneration-signatures-of
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.24.26361256v1?rss=1)
- **Published At:** 2026-08-27T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This study used structural MRI (sMRI) regional neurodegenerative biomarkers from two cohorts (ADNI and Knight-ADRC) totaling N = 1,756 to investigate relationships between **neuropsychiatric symptoms** (NPS) and brain atrophy across the Alzheimer's disease (AD) continuum. - The authors developed a deep neural network, called **NPSNet**, and compared its performance to other machine learning regressors for predicting NPS burden from sMRI-derived regional measures. - Explainability methods were integrated with NPSNet: **SHapley Additive exPlanations (SHAP)**, Local Interpretable Model-agnostic Explanations (LIME), and Layer-wise Relevance Propagation (LRP) to derive regional feature importance at the individual level. - In semi-simulated experiments with predefined regional perturbations, NPSNet combined with SHAP (NPSNetSHAP) recovered 100% of perturbed regions; NPSNetLIME recovered 90% and NPSNetLRP recovered 40%. - Model performance: NPSNet strongly predicted NPS scores in semi-simulated pooled data (Spearman ρ = 0.927, p < 2.2 × 10⁻³⁰⁸; fold-wise ρ = 0.912–0.963). In held-out experimental data (N = 1,756), NPSNet achieved the highest correlation (ρ = 0.387, p = 1.7 × 10⁻¹⁵), outperforming gradient boosting (ρ = 0.301), support vector regression (ρ = 0.266), and others (ρ < 0.266). - NPSNetSHAP produced individualized, distributed regional contribution patterns relevant to NPS prediction and revealed multivariate neurodegenerative signatures that differed between cognitively normal (CN) and MCI/AD groups, with the largest differences between CN and AD participants. - The study presents an explainable deep learning framework to identify distributed, individualized neurodegeneration signatures of **NPS** across the AD continuum using sMRI biomarkers. - Data were obtained from ADNI and Knight-ADRC; derived results are available upon reasonable request subject to data-use agreements. The authors declared no competing interests and reported IRB approval from Washington University in St. Louis.
## Clinical Analysis & Structured Key Points
Explainable Deep Learning Reveals Distributed Neurodegeneration Signatures of Neuropsychiatric Symptoms Across the Alzheimer's Continuum | medRxiv Skip to main content Explainable Deep Learning Reveals Distributed Neurodegeneration Signatures of Neuropsychiatric Symptoms Across the Alzheimer's Continuum Bahram Yaghooti , Saba Ishrat , Hoang Nam Le , Ram P. Sapkota , Taslim Murad , Deepa S. Thakuri , Dean F. Wong , Andrew Aschenbrenner , J. Philip Miller , Justin M. Long , Ginger E. Nicol , Eric J. Lenze , Alzheimer's Disease Neuroimaging Initiative , Ganesh B. Chand doi: https://doi.org/10.64898/2026.08.24.26361256 Bahram Yaghooti 1 Neuroimaging Informatics and Artificial Intelligence (NeuroAI) Laboratory, Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: byaghooti{at}wustl.edu Saba Ishrat 1 Neuroimaging Informatics and Artificial Intelligence (NeuroAI) Laboratory, Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hoang Nam Le 1 Neuroimaging Informatics and Artificial Intelligence (NeuroAI) Laboratory, Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ram P. Sapkota 1 Neuroimaging Informatics and Artificial Intelligence (NeuroAI) Laboratory, Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Taslim Murad 2 Neuroimaging Informatics and Artificial Intelligence (NeuroAI) Laboratory, Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA;Department of Computer Science, Institute of Business Adm; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Deepa S. Thakuri 3 Neuroimaging Informatics and Artificial Intelligence (NeuroAI) Laboratory, Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA;School of Medicine, University of Missouri, Columbia, MO,; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Dean F. Wong 4 Departments of Neurosurgery, Radiology and Psychiatry, Kahlert Institute of Addiction Medicine, University of Maryland Baltimore School of Medicine, Baltimore, MD, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Andrew Aschenbrenner 5 Department of Neurology, University of Kansas, Kansas City, KS, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site J. Philip Miller 6 Institute for Informatics, Data Science and Biostatistics, Washington University School of Medicine, St. Louis, MO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Justin M. Long 7 Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA;Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ginger E. Nicol 8 Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Eric J. Lenze 8 Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ganesh B. Chand 9 Neuroimaging Informatics and Artificial Intelligence (NeuroAI) Laboratory, Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA;Knight Alzheimer Disease Research Center, Washington Univ Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Neuropsychiatric symptoms (NPS) are increasingly recognized as critical components of the disease progression in Alzheimer's disease (AD), yet their relationship with neurodegeneration remain poorly characterized. We investigated the multivariate relationships between structural MRI (sMRI)-based regional neurodegenerative biomarkers and NPS using the Alzheimer's Disease Neuroimaging Initiative (ADNI) and Knight Alzheimer Disease Research Center (Knight-ADRC) cohorts (N = 1,756). The machine learning regression models were compared for NPS prediction, and the best-performing deep neural network (named NPSNet) was integrated with three feature-importance methods: SHapley Additive exPlanations (SHAP), Local Interpretable Model-agnostic Explanations (LIME), and Layer-wise Relevance Propagation (LRP). To establish a known ground truth, we introduced predefined regional perturbations into semi-simulated data and tested whether NPSNetSHAP, NPSNetLIME, and NPSNetLRP could recover them. The NPSNet strongly predicted NPS scores (pooled Spearman ρ = 0.927, p < 2.2 × 10⁻³⁰⁸; fold-wise ρ = 0.912-0.963) and NPSNetSHAP recovered all 100% perturbed regions, compared with 90% for NPSNetLIME and 40% for NPSNetLRP. In the experimental data (N = 1,756), the NPSNet produced the highest held-out correlation (ρ = 0.387, p = 1.7 × 10⁻¹⁵), exceeding gradient boosting (ρ = 0.301), support vector regression (ρ = 0.266), and others (ρ < 0.266). NPSNetSHAP identified individual-level regional contribution patterns relevant to NPS predictions. Comparing NPSNetSHAP attributions between cognitively normal (CN) and mild cognitive impairment (MCI)/AD groups revealed distributed multivariate neurodegenerative signatures of NPS, with the largest differences between CN and AD participants. This study introduces an explainable deep learning framework for identifying distributed, individualized neurodegeneration signatures of NPS burden across the AD continuum. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board (IRB) of Washington University in St. Louis gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data used in this study were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Knight Alzheimer Disease Research Center (Knight-ADRC). Access is governed by the respective data repositories and may require registration, application, approval, and acceptance of applicable data-use agreements. Derived results generated in this study are available from the corresponding authors upon reasonable request, subject to applicable human-subject and data-transfer requirements. Funder Information Declared National Institute on Aging, https://ror.org/049v75w11 , RF1AG087271 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Back to top Previous Next Posted August 27, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Explainable Deep Learning Reveals Distributed Neurodegeneration Signatures of Neuropsychiatric Symptoms Across the Alzheimer's Continuum Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Explainable Deep Learning Reveals Distributed Neurodegeneration Signatures of Neuropsychiatric Symptoms Across the Alzheimer's Continuum Bahram Yaghooti , Saba Ishrat , Hoang Nam Le , Ram P. Sapkota , Taslim Murad , Deepa S. Thakuri , Dean F. Wong , Andrew Aschenbrenner , J. Philip Miller , Justin M. Long , Ginger E. Nicol , Eric J. Lenze , Alzheimer's Disease Neuroimaging Initiative , Ganesh B. Chand medRxiv 2026.08.24.26361256; doi: https://doi.org/10.64898/2026.08.24.26361256 Share This Article: Copy Citation Tools Explainable Deep Learning Reveals Distributed Neurodegeneration Signatures of Neuropsychiatric Symptoms Across the Alzheimer's Continuum Bahram Yaghooti , Saba Ishrat , Hoang Nam Le , Ram P. Sapkota , Taslim Murad , Deepa S. Thakuri , Dean F. Wong , Andrew Aschenbrenner , J. Philip Miller , Justin M. Long , Ginger E. Nicol , Eric J. Lenze , Alzheimer's Disease Neuroimaging Initiative , Ganesh B. Chand medRxiv 2026.08.24.26361256; doi: https://doi.org/10.64898/2026.08.24.26361256 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (612) Allergy and Immunology (892) Anesthesia (325) Cardiovascular Medicine (4753) Dentistry and Oral Medicine (474) Dermatology (406) Emergency Medicine (640) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1610) Epidemiology (15800) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6967) Geriatric Medicine (726) Health Economics (1050) Health Informatics (4958) Health Policy (1422) Health Systems and Quality Improvement (1731) Hematology (578) HIV/AIDS (1329) Infectious Diseases (except HIV/AIDS) (16227) Intensive Care and Critical Care Medicine (1158) Medical Education (661) Medical Ethics (150) Nephrology (718) Neurology (7161) Nursing (360) Nutrition (1072) Obstetrics and Gynecology (1226) Occupational and Environmental Health (998) Oncology (3563) Ophthalmology (1032) Orthopedics (392) Otolaryngology (445) Pain Medicine (464) Palliative Medicine (139) Pathology (702) Pediatrics (1770) Pharmacology and Therapeutics (730) Primary Care Research (758) Psychiatry and Clinical Psychology (5812) Public and Global Health (9664) Radiology and Imaging (2371) Rehabilitation Medicine and Physical Therapy (1427) Respiratory Medicine (1236) Rheumatology (631) Sexual and Reproductive Health (762) Sports Medicine (572) Surgery (762) Toxicology (106) Transplantation (301) Urology (285)
## Related Clinical Research

- [Federal autism advisory committee highlights vaccines and shifts research priorities away from gen](https://medichelpline.com/clinical-feed/stat-news-2-at-a-federal-autism-advisory-committee-meeting-members-double-down-on-long.md)
- [Where Polygenic and Proteomic Risk Scores Diverge in Neurodegenerative Disease: Absorption and Co-](https://medichelpline.com/clinical-feed/medrxiv-10-absorption-and-co-expression-modules-show-where-polygenic-and-proteomic-risk.md)
- [Intranasal oxytocin alters the social salience network connectivity in adult men with autism](https://medichelpline.com/clinical-feed/medrxiv-20-intranasal-oxytocin-modulates-the-social-salience-network-in-adult-men-with.md)
- [Tanshinone IIA improves cognition in vascular dementia rats by modulating copper homeostasis](https://medichelpline.com/clinical-feed/plos-one-5-tanshinone-iia-attenuates-cognitive-impairment-in-vascular-dementia-rats-by.md)
- [High-dose vitamin D (≥5,000 IU) linked to better cognition in older adults with MCI and sleep prob](https://medichelpline.com/clinical-feed/medical-news-today-1-high-dose-vitamin-d-may-boost-brain-heath-in-older-adults-at-risk-of-dementia.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.